The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate-Reference-Cited by-同舟云学术

The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate

Published:2010-03 Issue:3 Volume:17 Page:225-234
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

Ward Patrick S.,Patel Jay,Wise David R.,Abdel-Wahab Omar,Bennett Bryson D.,Coller Hilary A.,Cross Justin R.,Fantin Valeria R.,Hedvat Cyrus V.,Perl Alexander E.,Rabinowitz Joshua D.,Carroll Martin,Su Shinsan M.,Sharp Kim A.,Levine Ross L.,Thompson Craig B.

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Oncology

Reference25 articles.

1. Separation and quantitation of water soluble cellular metabolites by hydrophilic interaction chromatography-tandem mass spectrometry;Bajad;J. Chromatogr. A,2006

2. Absolute quantitation of intracellular metabolite concentrations by an isotope ratio-based approach;Bennett;Nat. Protoc.,2008

3. Crystal structure of porcine mitochondrial NADP+-dependent isocitrate dehydrogenase complexed with Mn2+ and isocitrate. Insights into the enzyme mechanism;Ceccarelli;J. Biol. Chem.,2002

4. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate;Dang;Nature,2009

5. Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis;DeBerardinis;Proc. Natl. Acad. Sci. USA,2007

Cited by 1733 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The interplay of metabolic and epigenetic players in disease development;Biochemical and Biophysical Research Communications;2024-11

2. Replenishment of TCA cycle intermediates and long-noncoding RNAs regulation in breast cancer;Molecular and Cellular Endocrinology;2024-10

3. Relapse and resistance in acute myeloid leukemia post venetoclax: improving second lines therapy and combinations;Expert Review of Hematology;2024-09-13

4. Metabolism and epigenetics: drivers of tumor cell plasticity and treatment outcomes;Trends in Cancer;2024-09

5. Epigenetic-modifying agents: the potential game changers in the treatment of hematologic malignancies;Critical Reviews in Oncology/Hematology;2024-09